Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

NASDAQ: PTGX

    • Home
    • NASDAQ: PTGX
Company Drug

Takeda and Protagonist Submit Rusfertide NDA for Polycythemia Vera

Fineline Cube Jan 7, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) and Protagonist Therapeutics, Inc. (NASDAQ: PTGX) announced...

Recent updates

  • NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight
  • Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation
  • Viva Biotech and CMS Forge AI-Powered Drug Development Alliance
  • Hisun and ECNU Forge AI Drug Discovery Partnership
  • NMPA Issues Priority Review Guidelines for Clinically Urgent Overseas Drugs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Company Deals

Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation

Company Deals

Viva Biotech and CMS Forge AI-Powered Drug Development Alliance

Company Deals

Hisun and ECNU Forge AI Drug Discovery Partnership

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.